Polyrizon
Business Services · Israel · 1-10 Employees
View Company Info for Free
Overview
Headquarters
8 Hapnina St, Raanana, Raanana, 4321545,...Phone Number
+972 93740120Website
www.polyrizon-biotech.comRevenue
-Stock Symbol
PLRZIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Polyrizon
Polyrizon is a biotechnology company focused on developing innovative intranasal products that protect the nasal cavity and improve drug delivery. Its proprietary platforms are designed to create protective barriers against airborne particles while enhancing the targeted delivery of therapies through the nasal passage for respiratory and healthcare applications.Explore more
Polyrizon Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Polyrizon your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Polyrizon, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Polyrizon has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Polyrizon is spiking on competitors!
Earning: See what the market has to say on Polyrizon recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Polyrizon
Funding: Get notified immidiatlly once Polyrizon has new funding data
Click to see if Polyrizon had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Polyrizon launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Polyrizon is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Polyrizon is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Polyrizon.
Polyrizon Tech Stack
A closer look at the technologies used by Polyrizon
See more technologies
Most Recent Scoops
Project
Intellectual Property, Legal Affairs
Project
Product Development, Intellectual Property, Bioengineering, Medical Research, Pharmaceuticals, Clinical Operations, Contracts, Healthcare Technology, Manufacturing Operations
Initial Public Offering (IPO)
Initial Public Offering (IPO)
Polyrizon News & Media
Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway
New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier functionPolyrizon Receives Notice of European Patent Publication for Innovative Mucoadhesive Nasal Drug Delivery Technology
Raanana, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that the European Patent Office (EPO) has completed the technical preparations for the publication of the Company's European patent application entitled “Mucoadhesive Polymers for Nasal Drug Delivery.” The application was published under European publication number EPolyrizon Makes Strong Clinical Progress: Secures Three U.S. Sites for NASARIX™ Trial
Raanana, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced it has signed agreements with two additional U.S. clinical sites. This brings the total to three major contracted sites for its upcoming NASARIX™ (PL-14) clinical study.Polyrizon Advances Towards Human Clinical Trials: Secures First U.S. Clinical Site for NASARIX™ Allergy Blocker Clinical Trial
Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Polyrizon
Sign Up For FreeTo access detailed company insights
Polyrizon is a biotechnology company focused on developing innovative intranasal products that protect the nasal cavity and improve drug delivery. Its proprietary platforms are designed to create protective barriers against airborne particles while enhancing the targeted delivery of therapies through the nasal passage for respiratory and healthcare... Read More
